肛周克罗恩病患者停用抗TNF治疗后的复发情况
本研究基于香港、上海、台湾、马来西亚、泰国和新加坡多家机构的前瞻性炎症性肠病数据库,纳入1997年至2019年6月期间接受抗TNF治疗后停药的连续肛周克罗恩病患者,评估停药后肛周CD的复发率及相关因素。中位随访89个月后,78例患者中44例(56.4%)复发,12、36、60个月累积复发概率分别为50.8%、72.6%和78.0%。诊断时年龄较小与复发风险较高相关,复发后重启抗TNF治疗可使多数患者重获缓解,但超过四分之一复发患者需造口转流手术。
要点
- 肛周CD停用抗TNF后超半数复发,5年累积复发概率达78.0%。
- 诊断时年龄较小与停药后肛周CD复发风险升高独立相关。
- 复发后重启抗TNF治疗82.8%(24/29)可重获缓解,但27.3%需造口手术。
核心结论
- 超过半数肛周克罗恩病患者停用抗TNF治疗后出现复发,多数复发患者重启抗TNF可重获缓解,但超过四分之一复发患者需造口转流手术。
- 停药前进行影像学评估对肛周克罗恩病至关重要。
研究设计与样本
- 回顾性队列研究,数据来自香港、上海、台湾、马来西亚、泰国和新加坡多家机构的前瞻性炎症性肠病数据库,纳入1997年至2019年6月期间接受抗TNF治疗后停药的连续肛周克罗恩病患者78例。
主要发现
- 中位随访89个月(IQR 65-173个月)后,78例肛周CD患者中44例(56.4%)在停用抗TNF后复发。
- 肛周CD累积复发概率在12、36和60个月分别为50.8%、72.6%和78.0%。
- 44例复发患者中,29例接受抗TNF再治疗,其中24例(82.8%)诱导缓解;12例(27.3%)需造口转流手术,1例(2.3%)需直肠切除术。
临床怎么用
- 肛周克罗恩病患者停用抗TNF前应进行影像学评估,以识别停药后高复发风险者。
- 停药后需密切监测肛周CD复发,尤其是诊断时年龄较小的患者。
- 复发后重启抗TNF治疗可使多数患者重获缓解,但需警惕部分患者仍需造口转流手术。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Little is known of the outcome of patients with perianal Crohn's disease after stopping anti-tumour necrosis factor (TNF) therapy. AIM: To evaluate the rate of relapse in perianal Crohn's disease (CD) after stopping anti-TNF therapy. METHODS: Consecutive perianal CD patients treated with anti-TNF therapy with subsequent discontinuation were retrieved from prospective inflammatory bowel disease database of institutes in Hong Kong, Shanghai, Taiwan, Malaysia, Thailand and Singapore from 1997 to June 2019. Cumulative probability of perianal CD relapse was estimated using Kaplan-Meier method. RESULTS: After a median follow-up of 89 months (interquartile range [IQR]: 65-173 months), 44 of the 78 perianal CD patients (56.4%) relapsed after stopping anti-TNF, defined as increased fistula drainage or recurrence of previously healed fistula, after stopping anti-TNF therapy. Cumulative probabilities of perianal CD relapse were 50.8%, 72.6% and 78.0% at 12, 36 and 60 months, respectively. Younger age at diagnosis of CD [adjusted hazard ratio (HR): 1.04; 95% CI 1.01-1.09; P = .04] was associated with a higher chance of perianal CD relapse. Among those with perianal CD relapse (n = 44), retreatment with anti-TNF induced remission in 24 of 29 patients (82.8%). Twelve (27.3%) patients required defunctioning surgery and one (2.3%) required proctectomy. Maintenance with thiopurine was not associated with a reduced likelihood of relapse [HR = 1.10; 95% CI: 0.58-2.12; P = .77]. Among the 17 patients who achieved radiological remission of perianal CD, five (35.3%) developed relapse after stopping anti-TNF therapy after a median of 6 months. CONCLUSIONS: More than half of the perianal CD patients developed relapse after stopping anti-TNF therapy. Most regained response after resuming anti-TNF. However, more than one-fourth of the perianal CD patients with relapse required defunctioning surgery. Radiological assessment before stopping anti-TNF is crucial in perianal CD.
引用
- Mak JWY, Tang W, Yip TCF, et al. Stopping anti-tumour necrosis factor therapy in patients with perianal Crohn's disease. Aliment Pharmacol Ther. 2019. PMID: 31638274. doi:10.1111/apt.15547
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。